Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28321168 | 0.85 | RXRA (0.38) | RXRARXRBRXRGCES2L3MBTL1 | |
| SCHEMBL16991134 | 0.80 | IDO1 (0.43) | L3MBTL1RAB9APTPN5MAPTLMNA | |
| SCHEMBL1274838 | 0.78 | PDE2A (0.47) | PDE2A | |
| SCHEMBL2313884 | 0.78 | MRGPRX4 (0.43) | L3MBTL1RAB9ASLC6A4HCAR1CYP2C19 | |
| SCHEMBL3207554 | 0.78 | SYK (0.50) | SLC6A4ALDH1A1HPGDHSD17B10HTR2A | |
| SCHEMBL3192593 | 0.78 | KIF11 (0.38) | RXRARXRBRXRGLMNAALDH1A1 | |
| SCHEMBL12004607 | 0.78 | KDM1A (0.41) | L3MBTL1MAPTLMNAATMSLC6A4 | |
| SCHEMBL13881957 | 0.78 | L3MBTL1 (0.49) | RXRARXRBRXRGCES2L3MBTL1 | |
| SCHEMBL8194032 | 0.77 | L3MBTL1 (0.45) | L3MBTL1RAB9AMAPTNPSR1SLC6A4 | |
| SCHEMBL531610 | 0.77 | L3MBTL1 (0.45) | L3MBTL1RAB9AMAPTNPSR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4186882-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-31 | — | — | EP | disclosed |
| EP-2373605-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | UNIV DUNDEE (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-8507724-B2 | Compounds for use in the treatment of pain | THE UNIVERSITY OF DUNDEE (GB) | 2013-08-13 | — | — | US | disclosed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120029235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | THE UNIVERSITY OF DUNDEE (GB) | 2012-02-02 | — | — | US | disclosed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006008558-A1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | RXRA 3674/4885RXRB 3992/4885RXRG 3832/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | RXRA 3829/4885RXRB 2532/4885RXRG 3503/4885 |
| US-20230257408-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | SIRT1, SIRT3, HCCS | RXRA 822/4885RXRB 958/4885RXRG 942/4885 |
| US-20120029235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | RXRA 954/4885RXRB 894/4885RXRG 746/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | RXRA 1374/4885RXRB 1112/4885RXRG 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.